Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States

Digestive and Liver Disease

Volumn 43, Issue 1, 2011, Pages 66-72

  Rein, David B ^a   Wittenborn, John S ^a   Weinbaum, Cindy M ^b   Sabin, Miriam ^b   Smith, Bryce D ^b   Lesesne, Sarah B ^a  

^a RTI INTERNATIONAL   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Decompensated cirrhosis; Hepatocellular carcinoma; Liver failure; Simulation

Indexed keywords

AGE; ALCOHOL CONSUMPTION; ARTICLE; CHRONIC HEPATITIS; DISEASE COURSE; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONTE CARLO METHOD; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RACE; SEROPREVALENCE;

ADULT; ASYMPTOMATIC INFECTIONS; COMPUTER SIMULATION; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; FORECASTING; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; MONTE CARLO METHOD; MORBIDITY; UNITED STATES; YOUNG ADULT;

EID: 78649949431     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.05.006     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998, 47(RR-19):1-39.
2. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1-46.
3. Hyams K.C., Riddle J., Rubertone M., et al. Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Am J Epidemiol 2001, 153:764-770.
4. Wasley A., Grytdal S., Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008, 57:1-24.
5. Shepherd J., Brodin H., Cave C., et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004, 8:1-125. iii-iv.
6. de Bruijne J., Weegink C.J., Jansen P.L., et al. New developments in the antiviral treatment of hepatitis C. Vox Sang 2009.
7. Falck-Ytter Y., Kale H., Mullen K.D., et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
8. Allen S.A., Spaulding A.C., Osei A.M., et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003, 138:187-190.
9. Wong J.B., McQuillan G.M., McHutchison J.G., et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562-1569.
10. Deuffic-Burban S., Poynard T., Sulkowski M.S., et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007, 14:107-115.
11. Bennett W.G., Inoue Y., Beck J.R., et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997, 127:855-865.
12. Salomon J.A., Weinstein M.C., Hammitt J.K., et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002, 156:761-773.
13. Tanaka J., Kumada H., Ikeda K., et al. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003, 70:378-386.
14. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
15. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
16. Miriti MK, Billah K, Weinbaum C, et al. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S. Public Health Reports 2008;123:504-13.
17. Centers for Disease Control and Prevention National Health and Nutrition Examination Survey Data 2001-2006, National Center for Health Statistics (NCHS), Available from: URL: http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm.
18. Centers for Disease Control and Prevention National Health and Nutrition Examination Survey Data 1999-2004, National Center for Health Statistics (NCHS), Available from: URL: http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm.
19. Thomas D.L., Seeff L.B. Natural history of hepatitis C. Clin Liver Dis 2005, 9:383-398. vi.
20. Wright M., Grieve R., Roberts J., et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006, 10:1-113. iii.
21. United Kingdom Association of Cancer Registries 2004, United Kingdom Department of Health.
22. Planas R., Balleste B., Alvarez M.A., et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004, 40:823-830.
23. Ortner N., Cosway R. 2005 US organ and tissue transplant cost estimates and discussion 2005, Milliman Consultants and Actuaries, Seattle.
24. Jain A., Reyes J., Kashyap R., et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000, 232:490-500.
25. Davoli M., Perucci C.A., Rapiti E., et al. A persistent rise in mortality among injection drug users in Rome, 1980 through 1992. Am J Public Health 1997, 87:851-853.
26. Miller C.L., Kerr T., Strathdee S.A., et al. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J 2007, 4:1.
27. Joe G.W., Lehman W., Simpson D.D. Addict death rates during a four-year posttreatment follow-up. Am J Public Health 1982, 72:703-709.
28. Spittal P.M., Hogg R.S., Li K., et al. Drastic elevations in mortality among female injection drug users in a Canadian setting. AIDS Care 2006, 18:101-108.
29. Vlahov D., Wang C.L., Galai N., et al. Mortality risk among new onset injection drug users. Addiction 2004, 99:946-954.
30. Centers for Disease Control and Prevention National health and nutrition examination survey data 1999-2006, National Center for Health Statistics, Available from: URL: http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm.
31. Summary file: annual population estimates by age group and sex [database] 1991, U.S. Census Bureau, Available from: URL: http://www.census.gov/popest/archives/1990s/ [cited May 11, 2009].
32. American community survey: Table B01001: population-sex by age 2004, U.S. Census Bureau, Available from: URL: http://factfinder.census.gov/servlet/DatasetMainPageServlet?_program=ACS&_submenuId=&_lang=en&_ts= [cited May 11; 2009].
33. Centers for Disease Control and Prevention National health and nutrition examination survey data 2006, National Center for Health Statistics, Available from: URL: http://www.cdc.gov/nchs/about/major/nhanes/nhanes2003-2004/nhanes03_04.htm.
34. Armstrong G.L., Alter M.J., McQuillan G.M., et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31:777-782.
35. Arias E. United States life tables, 2004 2007, National Center for Health Statistics, Hyattsville, MD.
36. Centers for Disease Control and Prevention, National Center for Health Statistics National Health and Nutrition Examination Survey Data 1988-1994, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD.
37. Doubilet P., Begg C.B., Weinstein M.C., et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decision Making 1986, 5:157-177.
38. Davis G.L., Albright J.E., Cook S.F., et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338.
39. Kim W.R. The burden of hepatitis C in the United States. Hepatology 2002, 36(Suppl. 1):S30-S34.
40. United Network for Organ Sharing: Scientific Registry of Transplant Recipients. Number of Liver Transplants By Year, 2001-2006: recipients with a primary or secondary diagnosis code of HCV; 2007.
41. Wise M., Bialek S., Finelli L., et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008, 47:1128-1135.
42. Centers for Disease Control and Prevention. Statistics and Surveillance: Disease Burden from Hepatitis A, B, and C in the United States; 2009. Available from: URL: [cited July 31, 2009]. http://www.cdc.gov/hepatitis/statistics.htm.
43. Backus L.I., Phillips B.R., Boothroyd D.B., et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005, 39:613-619.
44. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666-1672.
45. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
46. United Network for Organ Sharing: Scientific Registry of Transplant Recipients. Organ Procurement and Transplantation Network (OPTN): Donors Recovered in the U.S. by Donor Type; 2009. Available from: URL: [cited February 14, 2009]. http://optn.transplant.hrsa.gov/latestData/rptData.asp.
47. Davstad I., Stenbacka M., Leifman A., et al. Patterns of illicit drug use and retention in a methadone program: a longitudinal study. J Opioid Manage 2007, 3:27-34.
48. Negro F., Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009, 16:681-688.
49. El-Zayadi A.R. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol 2009, 15:4993-4999.